Quality and Equity in Dialysis and Renal Transplantation
The Medicare End Stage Renal Disease (ESRD) Program began in 1973. Over the past 26 years, it has illustrated both the benefits of modern, high-technology medicine and the problems associated with it. Life of good quality has been extended for hundreds of thousands of people. However, the cost of th...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 1999-11, Vol.341 (22), p.1691-1693 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The Medicare End Stage Renal Disease (ESRD) Program began in 1973. Over the past 26 years, it has illustrated both the benefits of modern, high-technology medicine and the problems associated with it. Life of good quality has been extended for hundreds of thousands of people. However, the cost of the program has increased far beyond original estimates. In 1997, Medicare spent approximately $11.76 billion on the ESRD program, and total spending by all insurers was estimated to be about $15.64 billion.
1
The increase in cost came about mostly because long-term dialysis, originally intended for relatively young patients without systemic illnesses, . . . |
---|---|
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJM199911253412212 |